A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-181, a Monoclonal Antibody, as Monotherapy and in Combination With Another Anti-Cancer Therapy in Subjects With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 22 Jan 2018
At a glance
- Drugs ABBV 181 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 17 Jan 2018 Planned number of patients changed from 182 to 166.
- 17 Jan 2018 Planned End Date changed from 18 Sep 2019 to 18 Dec 2019.
- 17 Jan 2018 Planned primary completion date changed from 12 Jun 2018 to 14 Nov 2018.